Family

Loading Family data...

• 15 United States
• 10 France
• 8 Japan
• 7 China
• 5 Korea
• 2 Other

Patent Owner(s)

Patent Owner	Address
TEVA PHARMACEUTICAL INDUSTRIES LTD	TEL AVIV 6944020

International Classification(s)

• A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....

• 2017 Application Filing Year
• A61K Class
• 21227 Applications Filed
• 12841 Patents Issued To-Date
• 60.50 % Issued To-Date

Inventor(s)

Inventor Name	Address	# of filed Patents	Total Citations
Eyal, Eli	Petach-Tikva, IL	16	60
# of filed Patents : 16 Total Citations : 60
Hagai, Esther Lukasiewicz	Tel Aviv, IL	10	19
# of filed Patents : 10 Total Citations : 19
Melamed-Gal, Sigal	Chalfont, US	7	1
# of filed Patents : 7 Total Citations : 1
Wickenberg, Anna Kristina Sveinsdotter Teige	Lund, SE	8	20
# of filed Patents : 8 Total Citations : 20

Cited Art Landscape

Load Citation

• No Cited Art to Display

Loading Cited Art Landscape...

Patent Citation Ranking

• 0 Citation Count
• A61K Class

• 0 % this patent is cited more than
• 8 Age

Forward Cite Landscape

Load Citation

• No Forward Cites to Display

Loading Forward Cite Landscape...

Maintenance Fees

Fee	Large entity fee	small entity fee	micro entity fee	due date
7.5 Year Payment	$3600.00	$1800.00	$900.00	May 2, 2025
11.5 Year Payment	$7400.00	$3700.00	$1850.00	May 2, 2029

Fee	Large entity fee	small entity fee	micro entity fee
Surcharge - 7.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge - 11.5 year - Late payment within 6 months	$160.00	$80.00	$40.00
Surcharge after expiration - Late payment is unavoidable	$700.00	$350.00	$175.00
Surcharge after expiration - Late payment is unintentional	$1,640.00	$820.00	$410.00

Full Text

US Patent Application No: 2017/0312,264

USE OF LAQUINIMOD TO DELAY HUNTINGTON'S DISEASE PROGRESSION

---

Abstract

---

The subject invention provides methods of treating or delaying disease progression in a subject afflicted with Huntington's disease (HD) comprising administering to the subject 0.5-1.5 mg/day laquinimod. The subject invention also provides packages, therapeutic packages and pharmaceutical compositions, comprising one or more unit doses of 0.5-1.5 mg laquinimod for treating or delaying disease progression in a subject afflicted with HD. Also disclosed is use of laquinimod in the manufacture of a medicament comprising one or more unit doses of 0.5-1.5 mg laquinimod for use in treating or delaying disease progression in a subject afflicted HD.

---

 

---

Description

---

Claims

---

Claims data not available

---

Legal Events

• No Legal Status data available.